Mabqi

Mabqi is a Paris-based biotech founded in 2017, specializing in AI-driven antibody discovery. Its core platform, the LiteMab Antibody Discovery Studio, utilizes proprietary fully human synthetic libraries and high-throughput display technologies to generate therapeutic antibodies against challenging targets like GPCRs and ion channels. The company is building an internal oncology pipeline featuring pH-sensitive antibodies and is also positioned as a discovery partner for other biopharma entities. Mabqi operates as a private, pre-revenue company in the pre-clinical stage.

LiteMab Antibody Discovery Studio: A platform combining proprietary fully human synthetic antibody libraries with AI-powered phage display and yeast display technologies for high-throughput discovery and optimization of therapeutic antibodies against complex targets.

Mabqi competes in the crowded field of AI-driven drug discovery, particularly against companies like AbCellera, Generate Biomedicines, and Big Pharma internal efforts. Its differentiation lies in the specific combination of fully human synthetic libraries, dual display technologies, and a focus on conditionally active, format-ready antibodies for complex targets.